fda compounding glp-1 enforcement news New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Fifth Circuit probes FDA ban

The presentation highlighted that: Weight suppression can increase eating disorder risk regardless of BMI Larger degrees of suppression are associated with greater symptom severity Weight suppression is linked to medical instability and poorer recovery outcomes Weight suppression should be understood as a clinical concern rather than a marker of success

Heliyon 8:e11159 Salaheldin AT, Shehata MR, Sakr HI, Atia T, Mohamed AS (2022) Therapeutic potency of ovothiol a on ethanol-induced gastric ulcers in wistar rats

In this mockumentary comedy film, again directed by Rob Reiner, the band reunites after a 15-year break for one final concert

PlexusDx partners with licensed 503A compounding pharmacies to offer customized semaglutide and tirzepatide formulations at $189/mo month-to-month, or from $149/mo on the 6-month plan

TB-500:Thymosin Beta-4

Cancer Res 1999